Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VATCH (Vascular Anomaly Analysis for Therapy Choice): Phase II Study of Alpelisib Treatment in Subjects With TIE2/PIK3CA Pathway Driven Vascular Anomalies

NCT07543822 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT07543822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07543822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VATCH (Vascular Anomaly Analysis for Therapy Choice): Phase II Study of Alpelisib Treatment in Subjects With TIE2/PIK3CA Pathway Driven Vascular Anomalies
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 27, 2025
Completion date
August 27, 2030
Enrollment
61 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tie2/pik3ca pathway driven vascular anomalies, vascular anomalies, vascular anomaly